These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17923619

  • 41. Is there or is there not a place for anti-interferon antibodies in the decision making of multiple sclerosis treatment optimisation?
    Grigoriadis N, Deretzi G, Artemis N, Tascos N, Milonas I.
    Neurol Sci; 2006 Sep; 27 Suppl 5():S355-7. PubMed ID: 16998719
    [Abstract] [Full Text] [Related]

  • 42. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [Abstract] [Full Text] [Related]

  • 43. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis.
    Burks JS, Noronha A.
    Eur J Neurol; 2007 Jun 25; 14(6):e8-9; author reply e10-1. PubMed ID: 17539931
    [No Abstract] [Full Text] [Related]

  • 44. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 May 06; 70(19):1691-8. PubMed ID: 18458229
    [Abstract] [Full Text] [Related]

  • 45. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
    Prince HE, Lapé-Nixon M, Audette C, Van Horn K.
    J Neuroimmunol; 2007 Oct 06; 190(1-2):165-9. PubMed ID: 17889376
    [Abstract] [Full Text] [Related]

  • 46. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 47. Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta.
    Gibbs E, Tremlett H, Ball N, Hashimoto S.
    Eur J Neurol; 2008 Jan 04; 15(1):e4. PubMed ID: 18171383
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.
    Bendtzen K.
    J Interferon Cytokine Res; 2010 Oct 04; 30(10):759-66. PubMed ID: 20874253
    [Abstract] [Full Text] [Related]

  • 50. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
    Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G.
    J Immunoassay Immunochem; 2009 Oct 04; 30(1):40-50. PubMed ID: 19117201
    [Abstract] [Full Text] [Related]

  • 51. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul 04; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, Sala A, Marnetto F, Bertolotto A.
    Neurology; 2008 Dec 09; 71(24):1940-7. PubMed ID: 18971450
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the american academy of neurology.
    Mauskop A, Mathew N.
    Neurology; 2009 Apr 14; 72(15):1367; author reply 1367-8. PubMed ID: 19365063
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ.
    J Neurol Sci; 2008 Sep 15; 272(1-2):8-19. PubMed ID: 18620708
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.